In cancer research, DGLA at a dosage of 8 mg per mouse, administered intragastrically twice a week for 35 days, has been effective in suppressing the growth of xenograft tumors in mice implanted with human pancreatic cancer cells (BxPC-3) that have been transfected with delta-5-desaturase shRNA, highlighting its potential therapeutic applications in oncology^[3].

DGLA also reduces the expression of pro-inflammatory genes in human and mouse macrophages^[2].

Specifically, when administered at a concentration of 50 μM for 24 hours, DGLA lessens the phosphorylation of STAT1 on serine 727 induced by IFN-γ^[2].

Dihomo-γ-linolenic acid also diminishes the expression of MCP-1 and ICAM-1, which are induced by IL-1β and TNF-α, in human macrophages^[2].

Furthermore, DGLA has been shown to inhibit chemokine-driven monocytic migration and the formation of macrophage foam cells, which are key processes in the development of atherosclerosis^[2].